Oncology Update – 02 Mar 2026: FDA Full Approval for BRAFTOVI, FDA Accepts Giredestrant NDA and More

27 Visioni

Grazie! Condividilo con i tuoi amici!

Non hai gradito questo video. Grazie per il feedback!

Published Mar 9, 2026

This biweekly Oncology and Biopharma Regulatory Watch video recap highlights major regulatory approvals, label expansions, NDA acceptances, Phase 3 milestones, and expedited designations across lung, breast, colorectal, brain, and head and neck cancers in the US, EU, and Japan.

???? In this episode:

???? FIERCE-HN Phase 3 interim analysis completed

???? FDA approves monthly RYBREVANT FASPRO™ dosing

???? FDA accepts NDA for giredestrant in ESR1-mutated ER+ advanced breast cancer

???? EMA validates ENHERTU® Type II variation in early HER2+ breast cancer

???? EC approves new SC dosing regimens for RYBREVANT®

???? FDA Fast Track for SRN-101 in recurrent high-grade glioma

???????? Japan approves Alpha DaRT® in unresectable H&N cancer

???? FDA grants full approval to BRAFTOVI® combination in 1L mCRC

Chapetrs:
0:00 Introduction
0:08 FIERCE-HN Phase 3 interim analysis completed
0:44 FDA approves monthly RYBREVANT FASPRO™ dosing
1:15 FDA accepts NDA for giredestrant in ESR1-mutated ER+ advanced breast cancer
1:54 EMA validates ENHERTU® Type II variation in early HER2+ breast cancer
2:23 EC approves new SC dosing regimens for RYBREVANT®
2:46 FDA Fast Track for SRN-101 in recurrent high-grade glioma
3:11 Japan approves Alpha DaRT® in unresectable H&N cancer
3:34 FDA grants full approval to BRAFTOVI® combination in 1L mCRC
4:07 How to reach us

???? Stay Ahead in Oncology Research!
✅ Like, share, and subscribe for future updates on oncology
✅ Visit www.lqventures.com for expert healthcare insights and consulting services
✅ Contact LucidQuest at [email protected] for strategic guidance on Oncology innovations and clinical research
???? Turn on notifications so you never miss an update!

#OncologyandBiopharmaRegulatoryWatch #FDA #EMA #ClinicalTrials #PrecisionOncology #BreastCancer #LungCancer #ColorectalCancer #LucidQuest